Phenotypes associated with this allele

• Allele Symbol: Cd79a^tm1(cre)Reth
• Allele Name: targeted mutation 1, Michael Reth
• Allele ID: MGI:3687451
• Summary: 67 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
ht1	Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6	MGI:3687461
cn2	Atmin^tm1.1Jhh/Atmin^tm1.1Jhh Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Cd79a^tm1(cre)Reth/Cd79a^+ Tg(IghMyc)22Bri/0	B6.Cg-Bcl2l11^tm1.1Ast Cd79a^tm1(Cre)Reth Atmin^tm1.1Jhh Tg(IghMyc)22Bri	MGI:5755464
cn3	Atmin^tm1.1Jhh/Atmin^tm1.1Jhh Cd79a^tm1(cre)Reth/Cd79a^+	B6.Cg-Cd79a^tm1(Cre)Reth Atmin^tm1.1Jhh	MGI:5755460
cn4	Atmin^tm1.1Jhh/Atmin^tm1.1Jhh Cd79a^tm1(cre)Reth/Cd79a^+ Tg(IghMyc)22Bri/0	B6.Cg-Cd79a^tm1(Cre)Reth Atmin^tm1.1Jhh Tg(IghMyc)22Bri	MGI:5755462
cn5	Cd79a^tm1(cre)Reth/Cd79a^+ Huwe1^tm1.1Mak/Y	B6.Cg-Cd79a^tm1(cre)Reth Huwe1^tm1.1Mak	MGI:5314905
cn6	Cd79a^tm1(cre)Reth/Cd79a^+ Dynll1^tm1.1Jhh/Dynll1^tm1.1Jhh	B6.Cg-Dynll1^tm1.1Jhh Cd79a^tm1(Cre)Reth	MGI:5755454
cn7	Cd79a^tm1(cre)Reth/Cd79a^+ Dynll1^tm1.1Jhh/Dynll1^tm1.1Jhh Tg(IghMyc)22Bri/0	B6.Cg-Dynll1^tm1.1Jhh Cd79a^tm1(Cre)Reth Tg(IghMyc)22Bri	MGI:5755458
cn8	Cd79a^tm1(cre)Reth/Cd79a^+ Nr4a1^tm1Pcn/Nr4a1^tm1Pcn	involves: 129 * BALB/c	MGI:6717461
cn9	Grk2^tm1Gwd/Grk2^tm1Gwd Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129 * BALB/c * C57BL/6	MGI:5295055
cn10	Cd79a^tm1(cre)Reth/Cd79a^+ Inpp5d^tm1Rav/Inpp5d^tm1Rav	involves: 129 * BALB/c * C57BL/6	MGI:6376530
cn11	Cd79a^tm1(cre)Reth/Cd79a^+ Nr4a1^tm1Pcn/Nr4a1^tm1Pcn Nr4a3^em1Juz/Nr4a3^em1Juz	involves: 129 * BALB/c * C57BL/6	MGI:6717460
cn12	Inpp5d^tm1Rav/Inpp5d^tm1Rav Cd79a^tm1(cre)Reth/Cd79a^+ Tg(IghAb36-65)1Wys/0	involves: 129 * BALB/c * C57BL/6 * FVB/N	MGI:6376533
cn13	Ikzf1^tm3.1Mbu/Ikzf1^tm3.1Mbu Cd79a^tm1(cre)Reth/Cd79a^+ Rag2^tm1Fwa/Rag2^tm1Fwa	involves: 129P2/OlaHsd * 129S/SvEv * BALB/c * C57BL/6 * SJL	MGI:5698683
cn14	Srsf3^tm1Pjln/Srsf3^tm1Pjln Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129P2/OlaHsd * BALB/c	MGI:3687458
cn15	Syk^tm1Kuro/Syk^tm1Kuro Zap70^tm1Dlo/Zap70^tm1Dlo Cd79a^tm1(cre)Reth/?	involves: 129P2/OlaHsd * BALB/c * C57BL/6	MGI:3797235
cn16	Cd79a^tm1(cre)Reth/Cd79a^+ Eif4a1^tm1.1Bea/Eif4a1^tm1.1Bea	involves: 129P2/OlaHsd * BALB/c * C57BL/6	MGI:7646987
cn17	Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Trp53^tm1Brn/Trp53^tm1Brn Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129P2/OlaHsd * BALB/c * C57BL/6	MGI:5463974
cn18	Hdac1^tm1.1Pmt/Hdac1^tm1.1Pmt Hdac2^tm1.1Pmt/Hdac2^tm1.1Pmt Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129P2/OlaHsd * BALB/c * C57BL/6 * FVB/N	MGI:4440609
cn19	Commd8^tm1.1Ksuz/Commd8^tm1.1Ksuz Igh^tm1Mnz/Igh^+ Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129P2/OlaHsd * BALB/c * C57BL/6NSlc * SJL	MGI:6358358
cn20	Cd79a^tm1(cre)Reth/Cd79a^+ Ctnnbl1^tm1.1Crad/Ctnnbl1^tm1.1Crad	involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL	MGI:5795709
cn21	Cd79a^tm1(cre)Reth/Cd79a^+ Ikzf1^tm3.1Mbu/Ikzf1^tm3.1Mbu	involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL	MGI:5698681
cn22	Cd79a^tm1(cre)Reth/Cd79a^+ Huwe1^tm1.1Mak/Y Trp53^tm1Brn/Trp53^tm1Brn	involves: 129P2/OlaHsd * C57BL/6 * SJL	MGI:5314906
cn23	Cd79a^tm1(cre)Reth/Cd79a^+ Slc39a10^tm1.1Tfk/Slc39a10^tm1.1Tfk	involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J	MGI:6112652
cn24	Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Dicer1^tm1Mmk/Dicer1^tm1Mmk Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S1/Sv * BALB/c	MGI:3797396
cn25	Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S1/Sv * BALB/c * C57BL/6	MGI:5463975
cn26	Tbc1d10c^tm1.1Psou/Tbc1d10c^tm1.2Psou Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S2/SvPas * BALB/c * C57BL/6J	MGI:5578118
cn27	Cd79a^tm1(cre)Reth/Cd79a^tm1(cre)Reth Mzb1^tm1.1Rug/Mzb1^tm1.1Rug	involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL	MGI:6294908
cn28	Blnk^tm1Pjln/Blnk^tm1Pjln Cd79a^tm1(cre)Reth/Cd79a^tm1(cre)Reth Mzb1^tm1.1Rug/Mzb1^tm1.1Rug	involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL	MGI:6294907
cn29	Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk Traf3ip2^tm2Sbn/Traf3ip2^tm2Sbn Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S4/SvJae * BALB/c * C57BL/6	MGI:5462351
cn30	Dnmt1^tm2Jae/Dnmt1^tm2Jae Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S4/SvJae * BALB/c * C57BL/6	MGI:3687459
cn31	Cnn2^tm1.1Jin/Cnn2^tm1.1Jin Cnn3^tm1.1Hjum/Cnn3^tm1.1Hjum Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S6/SvEvTac * 129X1/SvJ * BALB/c	MGI:5825469
cn32	Cnn3^tm1.1Hjum/Cnn3^tm1.1Hjum Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S6/SvEvTac * BALB/c	MGI:5825467
cn33	Gt(ROSA)26Sor^tm2(CAG-Notch2*)Uzs/Gt(ROSA)26Sor^+ Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S6/SvEvTac * BALB/c * C57BL/6J	MGI:5301627
cn34	Ssb^tm1Rjma/Ssb^tm2.1Rjma Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S/SvEv * BALB/c	MGI:5569496
cn35	Cd79a^tm1(cre)Reth/Cd79a^+ Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor^+	involves: 129X1/SvJ * BALB/c * C57BL/6	MGI:3687456
cn36	Dicer1^tm1Mmk/Dicer1^tm1.1Mmk Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c	MGI:3797392
cn37	Nfatc1^tm1Rao/Nfatc1^tm1Rao Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c	MGI:5295253
cn38	Dicer1^tm1Mmk/Dicer1^tm1Mmk Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c	MGI:3797393
cn39	Dicer1^tm1Mmk/Dicer1^tm1Mmk Tg(IghelMD4)4Ccg/0 Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c	MGI:3797394
cn40	Nfatc1^tm1Rao/Nfatc1^tm1Rao Nfatc2^tm1Rao/Nfatc2^tm1Rao Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c	MGI:5295256
cn41	Grb2^tm1Lnit/Grb2^tm1Lnit Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * BALB/cJ	MGI:4949890
cn42	Cd79a^tm1(cre)Reth/Cd79a^+ Was^tm1.1Ldn/Was^tm1.1Ldn	involves: BALB/c * C57BL/6	MGI:5319484
cn43	Gt(ROSA)26Sor^tm1.1(Ubc-BCL3)Sbn/Gt(ROSA)26Sor^+ Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6	MGI:5574306
cn44	Tcf3^tm1(PBX1)Mlc/Tcf3^+ Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6	MGI:5825357
cn45	Cd79a^tm1(cre)Reth/Cd79a^+ Nfkbiz^tm1.1Muta/Nfkbiz^tm1.1Muta	involves: BALB/c * C57BL/6	MGI:5501491
cn46	Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6	MGI:5463972
cn47	Cd79a^tm1(cre)Reth/Cd79a^+ Was^tm1.1Ldn/Was^+	involves: BALB/c * C57BL/6	MGI:5319486
cn48	Cd79a^tm1(cre)Reth/Cd79a^+ Was^tm1.1Ldn/Y	involves: BALB/c * C57BL/6	MGI:5319485
cn49	Stim2^tm1.1Kuro/Stim2^tm1.1Kuro Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6	MGI:5008568
cn50	Stim1^tm1Kuro/Stim1^tm1Kuro Stim2^tm1.1Kuro/Stim2^tm1.1Kuro Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6	MGI:5008567
cn51	Stim1^tm1Kuro/Stim1^tm1Kuro Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6	MGI:5008566
cn52	Ikbkg^tm1.1Mpa/Ikbkg^tm1.1Mpa Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6	MGI:3687508
cn53	Cd79a^tm1(cre)Reth/Cd79a^+ Phf5a^tm1.1Oux/Phf5a^tm1.1Oux Tg(IghelMD4)4Ccg/0	involves: BALB/c * C57BL/6 * C57BL/6J	MGI:7611733
cn54	Bcl6^tm1.1Mtto/Bcl6^tm1.1Mtto Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6 * C57BL/6JJcl	MGI:5461328
cn55	Bcl6^tm1.1Mtto/Bcl6^tm1.1Mtto Cd79a^tm1(cre)Reth/Cd79a^+ Tg(Cd4-cre)1Cwi/0	involves: BALB/c * C57BL/6 * C57BL/6JJcl * DBA/2	MGI:5461331
cn56	Cd79a^tm1(cre)Reth/Cd79a^+ Eif4b^tm1.1Tnr/Eif4b^tm1.1Tnr Eif4h^tm1c(EUCOMM)Wtsi/Eif4h^tm1c(EUCOMM)Wtsi	involves: BALB/c * C57BL/6 * C57BL/6N	MGI:7646989
cn57	Cd79a^tm1(cre)Reth/Cd79a^+ Orai1^tm1Smua/Orai1^tm1Smua	involves: BALB/c * C57BL/6J	MGI:7625698
cn58	Cd79a^tm1(cre)Reth/Cd79a^+ Phf5a^tm1.1Oux/Phf5a^tm1.1Oux	involves: BALB/c * C57BL/6J	MGI:7611716
cn59	Cd79a^tm1(cre)Reth/Cd79a^+ Orai1^tm1Smua/Orai1^tm1Smua Orai3^em1.1Treb/Orai3^em1.1Treb	involves: BALB/c * C57BL/6J * C57BL/6N	MGI:7625702
cn60	Cd79a^tm1(cre)Reth/Cd79a^+ Orai3^em1.1Treb/Orai3^em1.1Treb	involves: BALB/c * C57BL/6J * C57BL/6N	MGI:7625703
cn61	Cd79a^tm1(cre)Reth/Cd79a^+ Dicer1^tm1Mmk/Dicer1^tm1Mmk Tg(BCL2)22Wehi/0	involves: BALB/c * C57BL/6JWehi * SJL/JWehi	MGI:3797395
cn62	Rnf31^tm1.1Kiwa/Rnf31^tm1.1Kiwa Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6NCrlj * CBA/JNCrlj	MGI:5550380
cn63	Cd79a^tm1(cre)Reth/Cd79a^+ Commd8^tm1.1Ksuz/Commd8^tm1.1Ksuz	involves: BALB/c * C57BL/6NSlc * SJL	MGI:6358356
cn64	Cd79a^tm1(cre)Reth/Cd79a^+ Commd3^tm1.1Ksuz/Commd3^tm1.1Ksuz	involves: BALB/c * C57BL/6NSlc * SJL	MGI:6358355
cn65	Sh3kbp1^tm1Kuro/Sh3kbp1^tm1Kuro Cd79a^tm1(cre)Reth/Cd79a^+ Gt(ROSA)26Sor^tm4(Ikbkb)Rsky/?	involves: BALB/c * C57BL/6 * NZB	MGI:5296788
cn66	Sh3kbp1^tm1Kuro/Sh3kbp1^tm1Kuro Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6 * NZB	MGI:5296787
cn67	Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6 * SJL	MGI:5316371

Genotype
MGI:3687461

ht1

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

normal phenotype

no abnormal phenotype detected ( J:113645 )

• numbers of cells in B subfractions in spleen and bone marrow is unchanged vs wild-type

Genotype
MGI:5755464

cn2

• Allelic Composition: Atmin^tm1.1Jhh/Atmin^tm1.1Jhh; Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast; Cd79a^tm1(cre)Reth/Cd79a⁺; Tg(IghMyc)22Bri/0
• Genetic Background: B6.Cg-Bcl2l11^tm1.1Ast Cd79a^tm1(Cre)Reth Atmin^tm1.1Jhh Tg(IghMyc)22Bri

neoplasm

increased lymphoma incidence ( J:230105 )

• compared with Tg(IghMyc)22Bri mice

Genotype
MGI:5755460

cn3

• Allelic Composition: Atmin^tm1.1Jhh/Atmin^tm1.1Jhh; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: B6.Cg-Cd79a^tm1(Cre)Reth Atmin^tm1.1Jhh

immune system

increased B cell apoptosis ( J:230105 )

• 2-fold

decreased B cell number ( J:230105 )

• 8-fold in the peripheral blood

decreased immature B cell number ( J:230105 )

• 10-fold compared with Cd79a^tm1(Cre)Reth/Cd79a⁺ or Tg(IghMyc)22Bri mice

decreased IgG1 level ( J:230105 )

hematopoietic system

increased B cell apoptosis ( J:230105 )

• 2-fold

decreased B cell number ( J:230105 )

• 8-fold in the peripheral blood

decreased immature B cell number ( J:230105 )

• 10-fold compared with Cd79a^tm1(Cre)Reth/Cd79a⁺ or Tg(IghMyc)22Bri mice

decreased IgG1 level ( J:230105 )

cellular

increased B cell apoptosis ( J:230105 )

• 2-fold

Genotype
MGI:5755462

cn4

• Allelic Composition: Atmin^tm1.1Jhh/Atmin^tm1.1Jhh; Cd79a^tm1(cre)Reth/Cd79a⁺; Tg(IghMyc)22Bri/0
• Genetic Background: B6.Cg-Cd79a^tm1(Cre)Reth Atmin^tm1.1Jhh Tg(IghMyc)22Bri

immune system

increased B cell apoptosis ( J:230105 )

• 15-fold

decreased B cell number ( J:230105 )

• 7.5-fold compared with Tg(IghMyc)22Bri mice

decreased immature B cell number ( J:230105 )

• 60-fold compared with Cd79a^tm1(Cre)Reth/Cd79a⁺ or Tg(IghMyc)22Bri mice

neoplasm

decreased lymphoma incidence ( J:230105 )

• compared with Tg(IghMyc)22Bri mice

increased tumor latency ( J:230105 )

• compared with Tg(IghMyc)22Bri mice

• however, the range to tumor types is the same

cellular

increased B cell apoptosis ( J:230105 )

• 15-fold

hematopoietic system

increased B cell apoptosis ( J:230105 )

• 15-fold

decreased B cell number ( J:230105 )

• 7.5-fold compared with Tg(IghMyc)22Bri mice

decreased immature B cell number ( J:230105 )

• 60-fold compared with Cd79a^tm1(Cre)Reth/Cd79a⁺ or Tg(IghMyc)22Bri mice

Genotype
MGI:5314905

cn5

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Huwe1^tm1.1Mak/Y
• Genetic Background: B6.Cg-Cd79a^tm1(cre)Reth Huwe1^tm1.1Mak

immune system

increased B cell apoptosis ( J:181705 )

♂ • in pre-B cells and mature B cells (1.5-fold)

decreased B cell proliferation ( J:181705 )

♂ • of transitional, marginal zone and follicular B cells

♂ • when B cells are stimulated with anti-IgM or anti-IgM plus anti-CD40

♂ • in B cells stimulated with LPS plus IL4

abnormal B cell differentiation ( J:181705 )

♂ • partially blocked at pre-B stage

abnormal class switch recombination ( J:181705 )

♂ • following stimulation of B cells with LPS or LPS plus IL4

decreased transitional stage B cell number ( J:181705 )

♂

decreased mature B cell number ( J:181705 )

♂ • 3-fold for recirculating mature B cells due to increased apoptosis

♂ • of B220+IgM+ B cells in the spleen

absent B-1a cells ( J:181705 )

♂ • virtually absent in the peritoneal cavity

decreased follicular B cell number ( J:181705 )

♂

decreased marginal zone B cell number ( J:181705 )

♂

decreased pre-B cell number ( J:181705 )

♂ • due to increased apoptosis

abnormal humoral immune response ( J:181705 )

♂ • mice stimulated with a T-independent antigen, TNP-Ficoll, fail to mount a TNP-specific IgM or IgG3 unlike control mice

♂ • mice stimulated with a T-dependent antigen, NP(15)CGG, produce less NP-specific IgG1 compared with control mice

decreased IgA level ( J:181705 )

♂ • 4.5-fold in unstimulated mice

decreased IgG1 level ( J:181705 )

♂ • 2-fold in unstimulated mice

♂ • in mice stimulated with NP(15)CGG

decreased IgG2a level ( J:181705 )

♂ • 32-fold in unstimulated mice

decreased IgG3 level ( J:181705 )

♂ • 37-fold in unstimulated mice

♂ • in mice stimulated with TNP-Ficoll

decreased IgM level ( J:181705 )

♂ • 2.5-fold in unstimulated mice

♂ • in mice stimulated with TNP-Ficoll

increased susceptibility to Riboviria infection ( J:181705 )

♂ • mice infected with vesicular stomatitis virus (VSV) exhibit delayed anti-VSV antibody production and reduced anti-VSV IgG levels compared with control mice

cellular

increased B cell apoptosis ( J:181705 )

♂ • in pre-B cells and mature B cells (1.5-fold)

decreased B cell proliferation ( J:181705 )

♂ • of transitional, marginal zone and follicular B cells

♂ • when B cells are stimulated with anti-IgM or anti-IgM plus anti-CD40

♂ • in B cells stimulated with LPS plus IL4

hematopoietic system

increased B cell apoptosis ( J:181705 )

♂ • in pre-B cells and mature B cells (1.5-fold)

decreased B cell proliferation ( J:181705 )

♂ • of transitional, marginal zone and follicular B cells

♂ • when B cells are stimulated with anti-IgM or anti-IgM plus anti-CD40

♂ • in B cells stimulated with LPS plus IL4

abnormal B cell differentiation ( J:181705 )

♂ • partially blocked at pre-B stage

abnormal class switch recombination ( J:181705 )

♂ • following stimulation of B cells with LPS or LPS plus IL4

decreased transitional stage B cell number ( J:181705 )

♂

decreased mature B cell number ( J:181705 )

♂ • 3-fold for recirculating mature B cells due to increased apoptosis

♂ • of B220+IgM+ B cells in the spleen

absent B-1a cells ( J:181705 )

♂ • virtually absent in the peritoneal cavity

decreased follicular B cell number ( J:181705 )

♂

decreased marginal zone B cell number ( J:181705 )

♂

decreased pre-B cell number ( J:181705 )

♂ • due to increased apoptosis

decreased IgA level ( J:181705 )

♂ • 4.5-fold in unstimulated mice

decreased IgG1 level ( J:181705 )

♂ • 2-fold in unstimulated mice

♂ • in mice stimulated with NP(15)CGG

decreased IgG2a level ( J:181705 )

♂ • 32-fold in unstimulated mice

decreased IgG3 level ( J:181705 )

♂ • 37-fold in unstimulated mice

♂ • in mice stimulated with TNP-Ficoll

decreased IgM level ( J:181705 )

♂ • 2.5-fold in unstimulated mice

♂ • in mice stimulated with TNP-Ficoll

Genotype
MGI:5755454

cn6

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Dynll1^tm1.1Jhh/Dynll1^tm1.1Jhh
• Genetic Background: B6.Cg-Dynll1^tm1.1Jhh Cd79a^tm1(Cre)Reth

immune system

abnormal B cell morphology ( J:230105 )

• 2-fold in pro-B/pre-B

decreased immature B cell number ( J:230105 )

• 8-fold in the bone marrow

decreased mature B cell number ( J:230105 )

• 4-fold in the spleen

decreased pre-B cell number ( J:230105 )

• in the bone marrow

hematopoietic system

abnormal B cell morphology ( J:230105 )

• 2-fold in pro-B/pre-B

decreased immature B cell number ( J:230105 )

• 8-fold in the bone marrow

decreased mature B cell number ( J:230105 )

• 4-fold in the spleen

decreased pre-B cell number ( J:230105 )

• in the bone marrow

Genotype
MGI:5755458

cn7

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Dynll1^tm1.1Jhh/Dynll1^tm1.1Jhh; Tg(IghMyc)22Bri/0
• Genetic Background: B6.Cg-Dynll1^tm1.1Jhh Cd79a^tm1(Cre)Reth Tg(IghMyc)22Bri

immune system

decreased immature B cell number ( J:230105 )

• greater than 50-fold

neoplasm

decreased lymphoma incidence ( J:230105 )

• compared with Tg(IghMyc)22Bri mice

hematopoietic system

decreased immature B cell number ( J:230105 )

• greater than 50-fold

Genotype
MGI:6717461

cn8

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Nr4a1^tm1Pcn/Nr4a1^tm1Pcn
• Genetic Background: involves: 129 * BALB/c

cellular

increased B cell proliferation ( J:306652 )

• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ lymphocytes and anti-immunoglobulin M (anti-IgM)

hematopoietic system

increased B cell proliferation ( J:306652 )

• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ lymphocytes and anti-immunoglobulin M (anti-IgM)

immune system

increased B cell proliferation ( J:306652 )

• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ lymphocytes and anti-immunoglobulin M (anti-IgM)

Genotype
MGI:5295055

cn9

• Allelic Composition: Grk2^tm1Gwd/Grk2^tm1Gwd; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129 * BALB/c * C57BL/6

immune system

decreased B cell number ( J:176118 )

• in the lymph nodes

increased B cell number ( J:176118 )

• in the spleen and blood

increased follicular B cell number ( J:176118 )

increased marginal zone B cell number ( J:176118 )

increased CD4-positive, alpha-beta T cell number ( J:176118 )

• in the spleen

increased CD8-positive, alpha-beta T cell number ( J:176118 )

• in the spleen

abnormal B cell physiology ( J:176118 )

• B cells and marginal zone B cells exhibit increased chemotactic response to S1P compared with control cells

• long-term accumulation of B cells in the lymph node is reduced compared with control cells

• marginal zone B cells exhibit decreased chemotactic response to CCL21 compared with control cells

• marginal zone B cells exhibit increased chemotactic response to SEW2871 (S1PR1-selective agonist) compared with control cells

• marginal zone B cell relocalization to the follicle induced by FTY720 treatment is delayed compared to in control mice

• splenic follicular dendritic cells exhibit reduced deposition of phycoerythrin-induced complexes compared with control cells

• however, transfer into a S1P null mouse restores normal lymph node accumulation

hematopoietic system

decreased B cell number ( J:176118 )

• in the lymph nodes

increased B cell number ( J:176118 )

• in the spleen and blood

increased follicular B cell number ( J:176118 )

increased marginal zone B cell number ( J:176118 )

increased CD4-positive, alpha-beta T cell number ( J:176118 )

• in the spleen

increased CD8-positive, alpha-beta T cell number ( J:176118 )

• in the spleen

abnormal B cell physiology ( J:176118 )

• B cells and marginal zone B cells exhibit increased chemotactic response to S1P compared with control cells

• long-term accumulation of B cells in the lymph node is reduced compared with control cells

• marginal zone B cells exhibit decreased chemotactic response to CCL21 compared with control cells

• marginal zone B cells exhibit increased chemotactic response to SEW2871 (S1PR1-selective agonist) compared with control cells

• marginal zone B cell relocalization to the follicle induced by FTY720 treatment is delayed compared to in control mice

• splenic follicular dendritic cells exhibit reduced deposition of phycoerythrin-induced complexes compared with control cells

• however, transfer into a S1P null mouse restores normal lymph node accumulation

Genotype
MGI:6376530

cn10

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Inpp5d^tm1Rav/Inpp5d^tm1Rav
• Genetic Background: involves: 129 * BALB/c * C57BL/6

mortality/aging

premature death ( J:178833 )

• mice have a less than 40% survival rate at 1 year

immune system

increased IgG level ( J:178833 )

• IgG deposition in kidney glomeruli is seen at 20 weeks of age

increased susceptibility to systemic lupus erythematosus ( J:178833 )

• mice show autoantibodies that are specifically seen in lupus; ssDNA, dsDNA, dsRNA and chromatin

increased autoantibody level ( J:178833 )

increased anti-nuclear antigen antibody level ( J:178833 )

• anti-nuclear antibodies in the sera in 20-week old mice

increased anti-chromatin antibody level ( J:178833 )

• mice exhibit chromatin autoantibodies at 8 weeks of age and at 20 weeks of age, mice show chromatin antibodies at amounts comparable to those seen in NZB/NZW mice

increased anti-double stranded DNA antibody level ( J:178833 )

increased anti-single stranded DNA antibody level ( J:178833 )

hematopoietic system

increased IgG level ( J:178833 )

• IgG deposition in kidney glomeruli is seen at 20 weeks of age

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
systemic lupus erythematosus		DOID:9074	OMIM:152700 OMIM:300809 OMIM:605480 OMIM:608437 OMIM:609903 OMIM:609939 OMIM:610065 OMIM:610066 OMIM:612254 OMIM:612378 OMIM:613145 OMIM:614420	J:178833

Genotype
MGI:6717460

cn11

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Nr4a1^tm1Pcn/Nr4a1^tm1Pcn; Nr4a3^em1Juz/Nr4a3^em1Juz
• Genetic Background: involves: 129 * BALB/c * C57BL/6

cellular

decreased B cell apoptosis ( J:306652 )

• greater survival of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)

increased B cell proliferation ( J:306652 )

• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)

hematopoietic system

decreased B cell apoptosis ( J:306652 )

• greater survival of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)

increased B cell proliferation ( J:306652 )

• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)

immune system

immune system phenotype ( J:306652 )

N • normal T cell and B cell development and homeostasis

decreased B cell apoptosis ( J:306652 )

• greater survival of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)

increased B cell proliferation ( J:306652 )

• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)

Genotype
MGI:6376533

cn12

• Allelic Composition: Inpp5d^tm1Rav/Inpp5d^tm1Rav; Cd79a^tm1(cre)Reth/Cd79a⁺; Tg(IghAb36-65)1Wys/0
• Genetic Background: involves: 129 * BALB/c * C57BL/6 * FVB/N

immune system

abnormal B cell negative selection ( J:178833 )

• peripheral B cell numbers are reduced by about 70%, suggesting enhanced negative selection

increased plasma cell number ( J:178833 )

• increase in frequency of plasma cells in the B cell population (4.96% of B cells compared to 0.04% in controls)

decreased B cell number ( J:178833 )

• peripheral B cell numbers are reduced by about 70%, suggesting enhanced negative selection

abnormal B cell anergy ( J:178833 )

• cell surface mIgM and mIgD are reduced 50% in B cells and B cells express reduced CD93, CD95, and CD80 indicating a loss of anergic B cells

• B cells lose features of anergy, including antigen unresponsiveness measured by BCR aggregation-induced Akt activation and calcium mobilization

• increase in frequency of B cells with activated phenotype (CD86+)

increased autoantibody level ( J:178833 )

• mice spontaneously express about 4-fold increased autoantibody by 20 weeks of age

hematopoietic system

abnormal B cell negative selection ( J:178833 )

• peripheral B cell numbers are reduced by about 70%, suggesting enhanced negative selection

increased plasma cell number ( J:178833 )

• increase in frequency of plasma cells in the B cell population (4.96% of B cells compared to 0.04% in controls)

decreased B cell number ( J:178833 )

• peripheral B cell numbers are reduced by about 70%, suggesting enhanced negative selection

Genotype
MGI:5698683

cn13

• Allelic Composition: Ikzf1^tm3.1Mbu/Ikzf1^tm3.1Mbu; Cd79a^tm1(cre)Reth/Cd79a⁺; Rag2^tm1Fwa/Rag2^tm1Fwa
• Genetic Background: involves: 129P2/OlaHsd * 129S/SvEv * BALB/c * C57BL/6 * SJL

hematopoietic system

decreased pro-B cell number ( J:209928 )

• three fold fewer pro-B cells

immune system

decreased pro-B cell number ( J:209928 )

• three fold fewer pro-B cells

Genotype
MGI:3687458

cn14

• Allelic Composition: Srsf3^tm1Pjln/Srsf3^tm1Pjln; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129P2/OlaHsd * BALB/c

immune system

decreased pro-B cell number ( J:113645 )

• strong reduction in number of B cell precursors is seen in bone marrow

decreased B cell number ( J:113645 )

• drastic reductions in B cell number are found in spleen, thymus, and bone marrow

decreased pre-B cell number ( J:113645 )

• drastic reduction in pre-B cells indicates that Sfrs3 is required for pre-B cell survival

hematopoietic system

decreased pro-B cell number ( J:113645 )

• strong reduction in number of B cell precursors is seen in bone marrow

decreased B cell number ( J:113645 )

• drastic reductions in B cell number are found in spleen, thymus, and bone marrow

decreased pre-B cell number ( J:113645 )

• drastic reduction in pre-B cells indicates that Sfrs3 is required for pre-B cell survival

Genotype
MGI:3797235

cn15

• Allelic Composition: Syk^tm1Kuro/Syk^tm1Kuro; Zap70^tm1Dlo/Zap70^tm1Dlo; Cd79a^tm1(cre)Reth/?
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6

immune system

abnormal pro-B cell differentiation ( J:134528 )

• there is a complete block pro-B cell differentation at the BP-1⁺HAS^low stage

hematopoietic system

abnormal pro-B cell differentiation ( J:134528 )

• there is a complete block pro-B cell differentation at the BP-1⁺HAS^low stage

Genotype
MGI:7646987

cn16

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Eif4a1^tm1.1Bea/Eif4a1^tm1.1Bea
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6

hematopoietic system

decreased pro-B cell number ( J:344730 )

• greater than 20-fold reduction in pro B or Hardy Fraction B cells in the bone marrow

• remaining pro B cells have only a minor reduction in EIF4A1 and a 10-fold increase in EIF4A2

decreased B cell number ( J:344730 )

• almost complete loss of splenic B cells

immune system

decreased pro-B cell number ( J:344730 )

• greater than 20-fold reduction in pro B or Hardy Fraction B cells in the bone marrow

• remaining pro B cells have only a minor reduction in EIF4A1 and a 10-fold increase in EIF4A2

decreased B cell number ( J:344730 )

• almost complete loss of splenic B cells

Genotype
MGI:5463974

cn17

• Allelic Composition: Atmin^tm1.2Jhh/Atmin^tm1.2Jhh; Trp53^tm1Brn/Trp53^tm1Brn; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6

immune system

decreased B cell number ( J:191832 )

• in the spleen but not as severe as in Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

decreased immature B cell number ( J:191832 )

• in the bone marrow but not as severe as in Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

hematopoietic system

decreased B cell number ( J:191832 )

• in the spleen but not as severe as in Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

decreased immature B cell number ( J:191832 )

• in the bone marrow but not as severe as in Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

Genotype
MGI:4440609

cn18

• Allelic Composition: Hdac1^tm1.1Pmt/Hdac1^tm1.1Pmt; Hdac2^tm1.1Pmt/Hdac2^tm1.1Pmt; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6 * FVB/N

hematopoietic system

increased B cell apoptosis ( J:157903 )

• of pre BII cells and large pre BII cells

decreased pro-B cell number ( J:157903 )

• numbers of pre BI cells are reduced by 60%-80%

arrested B cell differentiation ( J:157903 )

• block in B cell differentiation as early as the pre BI cell stage only 4.5% of pre B cells are in S phase compared to 80% for wild-type cells

decreased bone marrow cell number ( J:157903 )

• only a very few B cells remain

decreased B cell number ( J:157903 )

• spleen is virtually empty of circulating mature B cells

• in bone marrow, only a very few B cells remain

decreased pre-B cell number ( J:157903 )

• fewer than 1% of pre BII cell stage cells remain

abnormal spleen morphology ( J:157903 )

• virtually empty of circulating mature B cells

immune system

increased B cell apoptosis ( J:157903 )

• of pre BII cells and large pre BII cells

decreased pro-B cell number ( J:157903 )

• numbers of pre BI cells are reduced by 60%-80%

arrested B cell differentiation ( J:157903 )

• block in B cell differentiation as early as the pre BI cell stage only 4.5% of pre B cells are in S phase compared to 80% for wild-type cells

decreased B cell number ( J:157903 )

• spleen is virtually empty of circulating mature B cells

• in bone marrow, only a very few B cells remain

decreased pre-B cell number ( J:157903 )

• fewer than 1% of pre BII cell stage cells remain

abnormal spleen morphology ( J:157903 )

• virtually empty of circulating mature B cells

cellular

increased B cell apoptosis ( J:157903 )

• of pre BII cells and large pre BII cells

Genotype
MGI:6358358

cn19

• Allelic Composition: Commd8^tm1.1Ksuz/Commd8^tm1.1Ksuz; Igh^tm1Mnz/Igh⁺; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6NSlc * SJL

immune system

abnormal spleen B cell follicle morphology ( J:278399 )

• 3 hours after antigen injection, B cells fail to accumulate in the outer follicle instead had already arrived at the B-T boundary unlike in control cells

• however, B cells are distributed at the B-T boundary after 6 hours

hematopoietic system

abnormal spleen B cell follicle morphology ( J:278399 )

• 3 hours after antigen injection, B cells fail to accumulate in the outer follicle instead had already arrived at the B-T boundary unlike in control cells

• however, B cells are distributed at the B-T boundary after 6 hours

Genotype
MGI:5795709

cn20

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Ctnnbl1^tm1.1Crad/Ctnnbl1^tm1.1Crad
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL

immune system

immune system phenotype ( J:232010 )

N • mice exhibit normal splenic B cells numbers and early stages of B cell differentiation

abnormal B cell proliferation ( J:232010 )

• delayed entry into S phase on activation of resting, affecting follicular more than marginal zone B cells

decreased B cell proliferation ( J:232010 )

• in response to LPS or anti-CD40 stimulation

abnormal class switch recombination ( J:232010 )

• reduced immunoglobin class switching in splenic B cells

hematopoietic system

abnormal B cell proliferation ( J:232010 )

• delayed entry into S phase on activation of resting, affecting follicular more than marginal zone B cells

decreased B cell proliferation ( J:232010 )

• in response to LPS or anti-CD40 stimulation

abnormal class switch recombination ( J:232010 )

• reduced immunoglobin class switching in splenic B cells

cellular

abnormal B cell proliferation ( J:232010 )

• delayed entry into S phase on activation of resting, affecting follicular more than marginal zone B cells

decreased B cell proliferation ( J:232010 )

• in response to LPS or anti-CD40 stimulation

Genotype
MGI:5698681

cn21

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Ikzf1^tm3.1Mbu/Ikzf1^tm3.1Mbu
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL

hematopoietic system

abnormal B cell differentiation ( J:209928 )

increased pro-B cell number ( J:209928 )

• two fold more pro-B cells than in controls

• proliferation of c-Kit^hi pro-B cells is normal

• c-Kit^lo pro-B cells accumulate in the G1-G0 phases of the cell cycle

• cells are smaller with functionally rearranged immunoglobulin mu

• c-Kit^hi pro-B cells expressing immunoglobulin mu are increased

abnormal B cell number ( J:209928 )

• six fold reduction in total B cell number in bone marrow relative to controls

decreased pre-B cell number ( J:209928 )

• nearly complete loss of pre-B cells

neoplasm

neoplasm ( J:209928 )

N • evidence of B cell leukemias is not observed during a year of observation

immune system

abnormal B cell differentiation ( J:209928 )

increased pro-B cell number ( J:209928 )

• two fold more pro-B cells than in controls

• proliferation of c-Kit^hi pro-B cells is normal

• c-Kit^lo pro-B cells accumulate in the G1-G0 phases of the cell cycle

• cells are smaller with functionally rearranged immunoglobulin mu

• c-Kit^hi pro-B cells expressing immunoglobulin mu are increased

abnormal B cell number ( J:209928 )

• six fold reduction in total B cell number in bone marrow relative to controls

decreased pre-B cell number ( J:209928 )

• nearly complete loss of pre-B cells

Genotype
MGI:5314906

cn22

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Huwe1^tm1.1Mak/Y; Trp53^tm1Brn/Trp53^tm1Brn
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * SJL

immune system

immune system phenotype ( J:181705 )

♂N • bone marrow B cell development and stimulated and unstimulated splenic B cell proliferation are restored compared to in Cd79a^tm1(cre)Reth/Cd79a⁺ Huwe1^tm1.1Mak/Y mice

abnormal class switch recombination ( J:181705 )

♂ • to a greater extent than in Cd79a^tm1(cre)Reth/Cd79a⁺ Huwe1^tm1.1Mak/Y mice following stimulation of B cells with LPS or LPS plus IL4

absent B-1a cells ( J:181705 )

♂ • virtually absent in the peritoneal cavity

decreased IgG1 level ( J:181705 )

♂

decreased IgM level ( J:181705 )

♂

hematopoietic system

abnormal class switch recombination ( J:181705 )

♂ • to a greater extent than in Cd79a^tm1(cre)Reth/Cd79a⁺ Huwe1^tm1.1Mak/Y mice following stimulation of B cells with LPS or LPS plus IL4

absent B-1a cells ( J:181705 )

♂ • virtually absent in the peritoneal cavity

decreased IgG1 level ( J:181705 )

♂

decreased IgM level ( J:181705 )

♂

Genotype
MGI:6112652

cn23

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Slc39a10^tm1.1Tfk/Slc39a10^tm1.1Tfk
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J

hematopoietic system

decreased pro-B cell number ( J:213935 )

• decrease in B cell progenitors

decreased B cell number ( J:213935 )

• decrease in the number of CD19+ B cells in the spleen

spleen atrophy ( J:213935 )

decreased immunoglobulin level ( J:213935 )

decreased IgA level ( J:213935 )

decreased IgE level ( J:213935 )

decreased IgG1 level ( J:213935 )

decreased IgG2b level ( J:213935 )

decreased IgG2c level ( J:213935 )

decreased IgG3 level ( J:213935 )

decreased IgM level ( J:213935 )

immune system

decreased pro-B cell number ( J:213935 )

• decrease in B cell progenitors

decreased B cell number ( J:213935 )

• decrease in the number of CD19+ B cells in the spleen

spleen atrophy ( J:213935 )

decreased immunoglobulin level ( J:213935 )

decreased IgA level ( J:213935 )

decreased IgE level ( J:213935 )

decreased IgG1 level ( J:213935 )

decreased IgG2b level ( J:213935 )

decreased IgG2c level ( J:213935 )

decreased IgG3 level ( J:213935 )

decreased IgM level ( J:213935 )

Genotype
MGI:3797396

cn24

• Allelic Composition: Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast; Dicer1^tm1Mmk/Dicer1^tm1Mmk; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S1/Sv * BALB/c

immune system

decreased B cell number ( J:135783 )

• while B cell numbers are increased relative to in Cd79a^tm1(cre)Reth/Cd79a⁺ Bcl2l11^tm1.1Ast/Bcl2l11⁺ Dicer1^tm1Mmk/Dicer1^tm1Mmk mice, numbers are still lower than in wild-type mice

decreased mature B cell number ( J:135783 )

hematopoietic system

decreased B cell number ( J:135783 )

• while B cell numbers are increased relative to in Cd79a^tm1(cre)Reth/Cd79a⁺ Bcl2l11^tm1.1Ast/Bcl2l11⁺ Dicer1^tm1Mmk/Dicer1^tm1Mmk mice, numbers are still lower than in wild-type mice

decreased mature B cell number ( J:135783 )

Genotype
MGI:5463975

cn25

• Allelic Composition: Atmin^tm1.2Jhh/Atmin^tm1.2Jhh; Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S1/Sv * BALB/c * C57BL/6

immune system

immune system phenotype ( J:191832 )

N • B cell development is rescued compared with Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

enlarged spleen ( J:191832 )

• compared with control and Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased spleen weight ( J:191832 )

• compared with control and Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased B cell number ( J:191832 )

• compared with control and Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased immature B cell number ( J:191832 )

• compared with Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased pre-B cell number ( J:191832 )

• compared with Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

hematopoietic system

enlarged spleen ( J:191832 )

• compared with control and Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased spleen weight ( J:191832 )

• compared with control and Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased B cell number ( J:191832 )

• compared with control and Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased immature B cell number ( J:191832 )

• compared with Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased pre-B cell number ( J:191832 )

• compared with Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

growth/size/body

enlarged spleen ( J:191832 )

• compared with control and Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased spleen weight ( J:191832 )

• compared with control and Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

Genotype
MGI:5578118

cn26

• Allelic Composition: Tbc1d10c^tm1.1Psou/Tbc1d10c^tm1.2Psou; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S2/SvPas * BALB/c * C57BL/6J

immune system

abnormal B cell physiology ( J:211913 )

• accelerated antigen-specific B cell response in vivo in response to ovalbumin

increased IgG level ( J:211913 )

• increased anti-ovalbumin IgG titer after ovalbumin treatment

• CpG-DNA-treated mice exhibit renal IgG deposits unlike wild-type mice

increased IgM level ( J:211913 )

• in ovalbumin-treated mice

increased susceptibility to systemic lupus erythematosus ( J:211913 )

• CpG-DNA-treated mice exhibit increased anti-double stranded DNA antibody levels and renal IgG deposits compared with control mice

increased anti-double stranded DNA antibody level ( J:211913 )

• in CpG-DNA-treated mice

• however, untreated mice do not produce autoantibodies

hematopoietic system

abnormal B cell physiology ( J:211913 )

• accelerated antigen-specific B cell response in vivo in response to ovalbumin

increased IgG level ( J:211913 )

• increased anti-ovalbumin IgG titer after ovalbumin treatment

• CpG-DNA-treated mice exhibit renal IgG deposits unlike wild-type mice

increased IgM level ( J:211913 )

• in ovalbumin-treated mice

Genotype
MGI:6294908

cn27

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a^tm1(cre)Reth; Mzb1^tm1.1Rug/Mzb1^tm1.1Rug
• Genetic Background: involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL

hematopoietic system

increased pro-B cell number ( J:211639 )

• increased percentage of B220+ CD43+ pro-B cells in bone marrow

increased late pro-B cell number ( J:211639 )

• increased percentage of B220+ CD19+ muHC- CD25- late pro-B cells in bone marrow

abnormal B cell number ( J:211639 )

• decrease in CD19+ B cells in splenic B cell compartment

• reduced frequency of peritoneal B cells

• reduced percentage of B220hi CD43- recirculating B cells in bone marrow

• reduced percentage of B220int CD43- pre-B cells in bone marrow

• reduced number of muHC+ cells in IL7+ bone marrow B cell cultures

• normal frequency of cells with intracellular muHC in IL7+ bone marrow B cell cultures

decreased pre-B cell number ( J:211639 )

• reduced CD25+ pre-B cell number in bone marrow

small spleen ( J:211639 )

immune system

increased pro-B cell number ( J:211639 )

• increased percentage of B220+ CD43+ pro-B cells in bone marrow

increased late pro-B cell number ( J:211639 )

• increased percentage of B220+ CD19+ muHC- CD25- late pro-B cells in bone marrow

abnormal B cell number ( J:211639 )

• decrease in CD19+ B cells in splenic B cell compartment

• reduced frequency of peritoneal B cells

• reduced percentage of B220hi CD43- recirculating B cells in bone marrow

• reduced percentage of B220int CD43- pre-B cells in bone marrow

• reduced number of muHC+ cells in IL7+ bone marrow B cell cultures

• normal frequency of cells with intracellular muHC in IL7+ bone marrow B cell cultures

decreased pre-B cell number ( J:211639 )

• reduced CD25+ pre-B cell number in bone marrow

small spleen ( J:211639 )

Genotype
MGI:6294907

cn28

• Allelic Composition: Blnk^tm1Pjln/Blnk^tm1Pjln; Cd79a^tm1(cre)Reth/Cd79a^tm1(cre)Reth; Mzb1^tm1.1Rug/Mzb1^tm1.1Rug
• Genetic Background: involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL

hematopoietic system

abnormal bone marrow cell physiology ( J:211639 )

• 2.5-fold reduction in frequency of muHC+ lambda5+ cells in bone marrow

• increase in lambda5+ only bone marrow cells

Genotype
MGI:5462351

cn29

• Allelic Composition: Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk; Traf3ip2^tm2Sbn/Traf3ip2^tm2Sbn; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S4/SvJae * BALB/c * C57BL/6

immune system

increased germinal center B cell number ( J:191090 )

• mutants exhibit an increase in percentage and the total number of germinal center B cells compared to wild-type mice, although the total number of germinal center B cells is lower than in Fcgr2b homozygotes (that are also heterozygous for the floxed Traf3ip2 allele)

increased plasma cell number ( J:191090 )

glomerulonephritis ( J:191090 )

• develop glomerulonephritis comparable to single Fcgr2b homozygotes

hematopoietic system

increased germinal center B cell number ( J:191090 )

• mutants exhibit an increase in percentage and the total number of germinal center B cells compared to wild-type mice, although the total number of germinal center B cells is lower than in Fcgr2b homozygotes (that are also heterozygous for the floxed Traf3ip2 allele)

increased plasma cell number ( J:191090 )

renal/urinary system

glomerulonephritis ( J:191090 )

• develop glomerulonephritis comparable to single Fcgr2b homozygotes

Genotype
MGI:3687459

cn30

• Allelic Composition: Dnmt1^tm2Jae/Dnmt1^tm2Jae; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S4/SvJae * BALB/c * C57BL/6

immune system

abnormal B cell differentiation ( J:113645 )

• there is complete block of B cell development in spleen and bone marrow

decreased pro-B cell number ( J:113645 )

• proportion of CD19+ lymphocytes is 10% compared to 74% in wild-type

hematopoietic system

abnormal B cell differentiation ( J:113645 )

• there is complete block of B cell development in spleen and bone marrow

decreased pro-B cell number ( J:113645 )

• proportion of CD19+ lymphocytes is 10% compared to 74% in wild-type

Genotype
MGI:5825469

cn31

• Allelic Composition: Cnn2^tm1.1Jin/Cnn2^tm1.1Jin; Cnn3^tm1.1Hjum/Cnn3^tm1.1Hjum; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S6/SvEvTac * 129X1/SvJ * BALB/c

immune system

immune system phenotype ( J:237712 )

N • mice exhibit normal formation of precursor and mature B cell populations

Genotype
MGI:5825467

cn32

• Allelic Composition: Cnn3^tm1.1Hjum/Cnn3^tm1.1Hjum; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S6/SvEvTac * BALB/c

immune system

immune system phenotype ( J:237712 )

N • mice exhibit normal early B cell development

Genotype
MGI:5301627

cn33

• Allelic Composition: Gt(ROSA)26Sor^{tm2(CAG-Notch2*)Uzs}/Gt(ROSA)26Sor⁺; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S6/SvEvTac * BALB/c * C57BL/6J

immune system

arrested B cell differentiation ( J:179036 )

• B cell development is blocked at pro-B cell stage

decreased B cell number ( J:179036 )

• in the spleen, inguinal lymph nodes, and peritoneal cavity

increased T cell number ( J:179036 )

decreased splenocyte number ( J:179036 )

hematopoietic system

arrested B cell differentiation ( J:179036 )

• B cell development is blocked at pro-B cell stage

increased bone marrow cell number ( J:179036 )

• slightly

decreased B cell number ( J:179036 )

• in the spleen, inguinal lymph nodes, and peritoneal cavity

increased T cell number ( J:179036 )

decreased splenocyte number ( J:179036 )

Genotype
MGI:5569496

cn34

• Allelic Composition: Ssb^tm1Rjma/Ssb^tm2.1Rjma; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S/SvEv * BALB/c

immune system

immune system phenotype ( J:207687 )

N • mice exhibit normal splenic CD4+ and CD8+ T cells

arrested B cell differentiation ( J:207687 )

• total block at the pro-B cell to pre-B cell transition

decreased B cell number ( J:207687 )

• severe

small spleen ( J:207687 )

• hyposplenia

decreased spleen weight ( J:207687 )

decreased IgG level ( J:207687 )

• absent

decreased IgM level ( J:207687 )

• absent

hematopoietic system

arrested B cell differentiation ( J:207687 )

• total block at the pro-B cell to pre-B cell transition

decreased B cell number ( J:207687 )

• severe

small spleen ( J:207687 )

• hyposplenia

decreased spleen weight ( J:207687 )

decreased IgG level ( J:207687 )

• absent

decreased IgM level ( J:207687 )

• absent

Genotype
MGI:3687456

cn35

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129X1/SvJ * BALB/c * C57BL/6

homeostasis/metabolism

abnormal enzyme/coenzyme activity ( J:113645 )

• 97% of B lineage cells are EYFP-positive compared with 33% in Cd19^tm1(cre)Cgn-expressing mice indicating more efficient loxP recombination in developing B cells

Genotype
MGI:3797392

cn36

• Allelic Composition: Dicer1^tm1Mmk/Dicer1^tm1.1Mmk; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c

immune system

abnormal immunoglobulin V(D)J recombination ( J:135783 )

• usage of Dh elements and N nucleotide insertion into Igkappa is increased compared to in wild-type mice

decreased B cell number ( J:135783 )

hematopoietic system

abnormal immunoglobulin V(D)J recombination ( J:135783 )

• usage of Dh elements and N nucleotide insertion into Igkappa is increased compared to in wild-type mice

decreased B cell number ( J:135783 )

Genotype
MGI:5295253

cn37

• Allelic Composition: Nfatc1^tm1Rao/Nfatc1^tm1Rao; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c

homeostasis/metabolism

abnormal B cell calcium ion homeostasis ( J:177319 )

• B cells exhibit reduced alpha-IgM-mediated calcium flux compared with control cells

immune system

increased B cell apoptosis ( J:177319 )

• alpha-IgM-mediated

decreased B cell proliferation ( J:177319 )

• following BCR-induction

• mild defects in alpha-IgM-mediated proliferation

abnormal class switch recombination ( J:177319 )

• to IgG3 induced by T cell-independent type II antigens

decreased B cell number ( J:177319 )

• in the spleen

decreased B-1a cell number ( J:177319 )

• 5- to 10-fold in peritoneal washes

abnormal B cell calcium ion homeostasis ( J:177319 )

• B cells exhibit reduced alpha-IgM-mediated calcium flux compared with control cells

abnormal marginal zone B cell physiology ( J:177319 )

• marginal zone B cells exhibit decreased TNP-Ficoll binding compared with wild-type cells

decreased susceptibility to experimental autoimmune encephalomyelitis ( J:177319 )

hematopoietic system

increased B cell apoptosis ( J:177319 )

• alpha-IgM-mediated

decreased B cell proliferation ( J:177319 )

• following BCR-induction

• mild defects in alpha-IgM-mediated proliferation

abnormal class switch recombination ( J:177319 )

• to IgG3 induced by T cell-independent type II antigens

decreased B cell number ( J:177319 )

• in the spleen

decreased B-1a cell number ( J:177319 )

• 5- to 10-fold in peritoneal washes

abnormal B cell calcium ion homeostasis ( J:177319 )

• B cells exhibit reduced alpha-IgM-mediated calcium flux compared with control cells

abnormal marginal zone B cell physiology ( J:177319 )

• marginal zone B cells exhibit decreased TNP-Ficoll binding compared with wild-type cells

cellular

increased B cell apoptosis ( J:177319 )

• alpha-IgM-mediated

decreased B cell proliferation ( J:177319 )

• mild defects in alpha-IgM-mediated proliferation

• following BCR-induction

Genotype
MGI:3797393

cn38

• Allelic Composition: Dicer1^tm1Mmk/Dicer1^tm1Mmk; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c

immune system

decreased immature B cell number ( J:135783 )

• hardly detected

increased pro-B cell number ( J:135783 )

• in the bone marrow

arrested B cell differentiation ( J:135783 )

• B cell development is almost completely blocked at the pro- to pre-B cell transition

decreased mature B cell number ( J:135783 )

• hardly detected

decreased pre-B cell number ( J:135783 )

• in the bone marrow due to a massive increase in apoptosis

hematopoietic system

decreased immature B cell number ( J:135783 )

• hardly detected

increased pro-B cell number ( J:135783 )

• in the bone marrow

arrested B cell differentiation ( J:135783 )

• B cell development is almost completely blocked at the pro- to pre-B cell transition

decreased mature B cell number ( J:135783 )

• hardly detected

decreased pre-B cell number ( J:135783 )

• in the bone marrow due to a massive increase in apoptosis

Genotype
MGI:3797394

cn39

• Allelic Composition: Dicer1^tm1Mmk/Dicer1^tm1Mmk; Tg(IghelMD4)4Ccg/0; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c

immune system

decreased B cell number ( J:135783 )

• while B cell numbers are increased relative to in Cd79a^tm1(cre)Reth/Cd79a⁺ Dicer1^tm1Mmk/Dicer1^tm1Mmk mice, numbers are still lower than in wild-type mice

decreased mature B cell number ( J:135783 )

hematopoietic system

decreased B cell number ( J:135783 )

• while B cell numbers are increased relative to in Cd79a^tm1(cre)Reth/Cd79a⁺ Dicer1^tm1Mmk/Dicer1^tm1Mmk mice, numbers are still lower than in wild-type mice

decreased mature B cell number ( J:135783 )

Genotype
MGI:5295256

cn40

• Allelic Composition: Nfatc1^tm1Rao/Nfatc1^tm1Rao; Nfatc2^tm1Rao/Nfatc2^tm1Rao; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c

immune system

abnormal B cell physiology ( J:177319 )

• stimulated B cells exhibit reduced ability to induced T cell proliferation

decreased interleukin-2 secretion ( J:177319 )

• from stimulated B cells

hematopoietic system

abnormal B cell physiology ( J:177319 )

• stimulated B cells exhibit reduced ability to induced T cell proliferation

Genotype
MGI:4949890

cn41

• Allelic Composition: Grb2^tm1Lnit/Grb2^tm1Lnit; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * BALB/cJ

immune system

abnormal B cell differentiation ( J:171222 )

• in an adoptive transfer experiment, B cells are at a competitive disadvantage to wild-type B cells

decreased transitional stage T1 B cell number ( J:171222 )

decreased transitional stage T2 B cell number ( J:171222 )

increased plasma cell number ( J:171222 )

• IgM-secreting plasma cells

decreased B cell number ( J:171222 )

• in peripheral blood

decreased mature B cell number ( J:171222 )

• mice exhibit a reduction in recirculating, mature (IgM+B220^hi fraction F) B cells in the bone marrow compared with Grb2^tm1Lnit homozygote controls

• the number of mature B cells in the spleen is half that in wild-type mice

• however, mice exhibit normal numbers of marginal zone B cells and B1 cells in the spleen and peritoneal cavity

decreased follicular B cell number ( J:171222 )

decreased spleen germinal center number ( J:171222 )

• in mice immunized with sheep red blood cell

decreased spleen germinal center size ( J:171222 )

• in mice immunized with sheep red blood cell

abnormal B cell physiology ( J:171222 )

• mice exhibit reduced Brd-U labeled T1/marginal zone B cells compared with cells from Grb2^tm1Lnit homozygote controls

• however, bone marrow pre-B and immature B cell proliferation is normal

increased B cell apoptosis ( J:171222 )

• immature and mature B cells exhibit a slight increase in spontaneous apoptosis compared to in Grb2^tm1Lnit homozygote controls

increased B cell proliferation ( J:171222 )

• after anti-IgM or LPS stimulation

decreased IgG level ( J:171222 )

• in response to secondary exposure to human cytomegalovirus-derived virus-like particles

• however, primary IgG response is normal

decreased IgG3 level ( J:171222 )

• in TNP-ficoll treated mice

increased IgM level ( J:171222 )

• 10-fold in unstimulated mice

• however, IgM response to TNP-ficoll is normal

abnormal memory B cell physiology ( J:171222 )

• mice exhibit impaired memory response to human cytomegalovirus-derived virus-like particles compared with Grb2^tm1Lnit homozygote controls

hematopoietic system

abnormal B cell differentiation ( J:171222 )

• in an adoptive transfer experiment, B cells are at a competitive disadvantage to wild-type B cells

decreased transitional stage T1 B cell number ( J:171222 )

decreased transitional stage T2 B cell number ( J:171222 )

increased plasma cell number ( J:171222 )

• IgM-secreting plasma cells

decreased B cell number ( J:171222 )

• in peripheral blood

decreased mature B cell number ( J:171222 )

• mice exhibit a reduction in recirculating, mature (IgM+B220^hi fraction F) B cells in the bone marrow compared with Grb2^tm1Lnit homozygote controls

• the number of mature B cells in the spleen is half that in wild-type mice

• however, mice exhibit normal numbers of marginal zone B cells and B1 cells in the spleen and peritoneal cavity

decreased follicular B cell number ( J:171222 )

decreased spleen germinal center number ( J:171222 )

• in mice immunized with sheep red blood cell

decreased spleen germinal center size ( J:171222 )

• in mice immunized with sheep red blood cell

abnormal B cell physiology ( J:171222 )

• mice exhibit reduced Brd-U labeled T1/marginal zone B cells compared with cells from Grb2^tm1Lnit homozygote controls

• however, bone marrow pre-B and immature B cell proliferation is normal

increased B cell apoptosis ( J:171222 )

• immature and mature B cells exhibit a slight increase in spontaneous apoptosis compared to in Grb2^tm1Lnit homozygote controls

increased B cell proliferation ( J:171222 )

• after anti-IgM or LPS stimulation

decreased IgG level ( J:171222 )

• in response to secondary exposure to human cytomegalovirus-derived virus-like particles

• however, primary IgG response is normal

decreased IgG3 level ( J:171222 )

• in TNP-ficoll treated mice

increased IgM level ( J:171222 )

• 10-fold in unstimulated mice

• however, IgM response to TNP-ficoll is normal

abnormal memory B cell physiology ( J:171222 )

• mice exhibit impaired memory response to human cytomegalovirus-derived virus-like particles compared with Grb2^tm1Lnit homozygote controls

cellular

increased B cell apoptosis ( J:171222 )

• immature and mature B cells exhibit a slight increase in spontaneous apoptosis compared to in Grb2^tm1Lnit homozygote controls

increased B cell proliferation ( J:171222 )

• after anti-IgM or LPS stimulation

Genotype
MGI:5319484

cn42

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Was^tm1.1Ldn/Was^tm1.1Ldn
• Genetic Background: involves: BALB/c * C57BL/6

immune system

increased germinal center B cell number ( J:182528 )

♀ • in the spleen and lymph nodes

increased plasma cell number ( J:182528 )

♀ • increase in the proportion of CD19+ CD138^hi plasma cells

decreased B cell number ( J:182528 )

♀ • B cell lymphopenia

decreased mature B cell number ( J:182528 )

♀ • decrease in the percentage and absolute number of bone marrow B220 hi mature recirculating B cells

♀ • decrease in the proportion and number of CD19+ B cells in the spleen

decreased follicular B cell number ( J:182528 )

♀ • decrease in absolute number but not the proportion of follicular B cells

decreased marginal zone B cell number ( J:182528 )

♀ • decrease in the percentage and absolute number of marginal zone B cells

♀ • the ring of B220+ CD1d+ MZ B cells that normally surrounds MOMA-expressing metallophilic macrophages is almost absent

abnormal B cell physiology ( J:182528 )

♀ • virtual abrogation of IgM and IgG pneumococcus polysaccharide specific Ab responses

♀ • abrogation of the early response to immunization with UV inactivated vesicular stomatitis virus

increased IgM level ( J:182528 )

♀ • elevated total serum levels and spontaneous production of IgM Abs specific for trinitrophenyl and phosphocholine

increased autoantibody level ( J:182528 )

♀

increased anti-chromatin antibody level ( J:182528 )

♀

increased anti-double stranded DNA antibody level ( J:182528 )

♀

increased anti-single stranded DNA antibody level ( J:182528 )

♀

renal/urinary system

abnormal renal corpuscle morphology ( J:182528 )

♀ • modest degree of glomerular damage

hematopoietic system

increased germinal center B cell number ( J:182528 )

♀ • in the spleen and lymph nodes

increased plasma cell number ( J:182528 )

♀ • increase in the proportion of CD19+ CD138^hi plasma cells

decreased B cell number ( J:182528 )

♀ • B cell lymphopenia

decreased mature B cell number ( J:182528 )

♀ • decrease in the percentage and absolute number of bone marrow B220 hi mature recirculating B cells

♀ • decrease in the proportion and number of CD19+ B cells in the spleen

decreased follicular B cell number ( J:182528 )

♀ • decrease in absolute number but not the proportion of follicular B cells

decreased marginal zone B cell number ( J:182528 )

♀ • decrease in the percentage and absolute number of marginal zone B cells

♀ • the ring of B220+ CD1d+ MZ B cells that normally surrounds MOMA-expressing metallophilic macrophages is almost absent

abnormal B cell physiology ( J:182528 )

♀ • virtual abrogation of IgM and IgG pneumococcus polysaccharide specific Ab responses

♀ • abrogation of the early response to immunization with UV inactivated vesicular stomatitis virus

increased IgM level ( J:182528 )

♀ • elevated total serum levels and spontaneous production of IgM Abs specific for trinitrophenyl and phosphocholine

Genotype
MGI:5574306

cn43

• Allelic Composition: Gt(ROSA)26Sor^{tm1.1(Ubc-BCL3)Sbn}/Gt(ROSA)26Sor⁺; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6

immune system

decreased B cell proliferation ( J:207111 )

• slightly less in LPS-stimulated marginal zone

• however, proliferation of alphaIgM-stimulated follicular B cells is not significantly different from that of wild-type cells

decreased follicular B cell number ( J:207111 )

• FO I B cells

decreased marginal zone B cell number ( J:207111 )

increased follicular B cell number ( J:207111 )

• total and FO II B cells

hematopoietic system

decreased B cell proliferation ( J:207111 )

• slightly less in LPS-stimulated marginal zone

• however, proliferation of alphaIgM-stimulated follicular B cells is not significantly different from that of wild-type cells

decreased follicular B cell number ( J:207111 )

• FO I B cells

decreased marginal zone B cell number ( J:207111 )

increased follicular B cell number ( J:207111 )

• total and FO II B cells

cellular

decreased B cell proliferation ( J:207111 )

• slightly less in LPS-stimulated marginal zone

• however, proliferation of alphaIgM-stimulated follicular B cells is not significantly different from that of wild-type cells

Genotype
MGI:5825357

cn44

• Allelic Composition: Tcf3^tm1(PBX1)Mlc/Tcf3⁺; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6

neoplasm

increased B cell acute lymphoblastic leukemia incidence ( J:226241 )

• mice develop acute leukemia with an incidence of 53% at 12 months of age

• leukemia cells are present in the bone marrow, spleen, lymph nodes and infiltrate multiple organs, including the CNS

• 94% of leukemias have a B cell precursor phenotype

hematopoietic system

enlarged spleen ( J:226241 )

• in leukemic mice

arrested B cell differentiation ( J:226241 )

• leukemic blasts are arrested at the pro/pre-B stage of B cell precursor differentiation

anemia ( J:226241 )

• in leukemic mice

thrombocytopenia ( J:226241 )

• in leukemic mice

decreased B cell number ( J:226241 )

• a lower percentage of B cells are seen in the peripheral blood over a 30 week period in healthy preleukemic mice

decreased immature B cell number ( J:226241 )

• decrease in immature and recirculating B cells in the bone marrow in healthy preleukemic mice

increased leukocyte cell number ( J:226241 )

• leukemic mice present with leukocytosis

immune system

enlarged spleen ( J:226241 )

• in leukemic mice

arrested B cell differentiation ( J:226241 )

• leukemic blasts are arrested at the pro/pre-B stage of B cell precursor differentiation

decreased B cell number ( J:226241 )

• a lower percentage of B cells are seen in the peripheral blood over a 30 week period in healthy preleukemic mice

decreased immature B cell number ( J:226241 )

• decrease in immature and recirculating B cells in the bone marrow in healthy preleukemic mice

increased leukocyte cell number ( J:226241 )

• leukemic mice present with leukocytosis

enlarged lymph nodes ( J:226241 )

• in leukemic mice

liver/biliary system

enlarged liver ( J:226241 )

• in leukemic mice

growth/size/body

enlarged liver ( J:226241 )

• in leukemic mice

enlarged spleen ( J:226241 )

• in leukemic mice

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
acute lymphoblastic leukemia		DOID:9952	OMIM:247640 OMIM:613065	J:226241

Genotype
MGI:5501491

cn45

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Nfkbiz^tm1.1Muta/Nfkbiz^tm1.1Muta
• Genetic Background: involves: BALB/c * C57BL/6

immune system

immune system phenotype ( J:194832 )

N • lack inflammation up to 30 weeks of age

Genotype
MGI:5463972

cn46

• Allelic Composition: Atmin^tm1.2Jhh/Atmin^tm1.2Jhh; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6

Small spleen size in Atmin^tm1.2Jhh/Atmin^tm1.2Jhh/ Cd79a^tm1(cre)Reth/Cd79a⁺ mice

immune system

abnormal B cell differentiation ( J:191832 )

• impaired in a cell-intrinsic manner

• not rescued by provision of a prearranged BCR

decreased immature B cell number ( J:191832 )

• more than 7-fold in the bone marrow

decreased mature B cell number ( J:191832 )

• more than 7-fold in the spleen

decreased pre-B cell number ( J:191832 )

• 3-fold in the bone marrow

small spleen ( J:191832 )

• 2-fold

decreased spleen weight ( J:191832 )

abnormal B cell physiology ( J:191832 )

• immature and transitional B cells exhibit a 3-fold increase in cell death compared with control cells

hematopoietic system

abnormal B cell differentiation ( J:191832 )

• impaired in a cell-intrinsic manner

• not rescued by provision of a prearranged BCR

decreased immature B cell number ( J:191832 )

• more than 7-fold in the bone marrow

decreased mature B cell number ( J:191832 )

• more than 7-fold in the spleen

decreased pre-B cell number ( J:191832 )

• 3-fold in the bone marrow

small spleen ( J:191832 )

• 2-fold

decreased spleen weight ( J:191832 )

abnormal B cell physiology ( J:191832 )

• immature and transitional B cells exhibit a 3-fold increase in cell death compared with control cells

Genotype
MGI:5319486

cn47

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Was^tm1.1Ldn/Was⁺
• Genetic Background: involves: BALB/c * C57BL/6

immune system

abnormal B cell proliferation ( J:182528 )

♀ • increased proliferation in cells lacking expression of Was compared to cells expressing Was in the follicular and germinal center B cell populations

abnormal B cell number ( J:182528 )

♀ • while B cell numbers are similar to controls, the distribution of cells lacking expression of Was is biased against marginal zone B cells

♀ • enrichment of null cells in the germinal center cell and plasma cell populations

hematopoietic system

abnormal B cell proliferation ( J:182528 )

♀ • increased proliferation in cells lacking expression of Was compared to cells expressing Was in the follicular and germinal center B cell populations

abnormal B cell number ( J:182528 )

♀ • while B cell numbers are similar to controls, the distribution of cells lacking expression of Was is biased against marginal zone B cells

♀ • enrichment of null cells in the germinal center cell and plasma cell populations

cellular

abnormal B cell proliferation ( J:182528 )

♀ • increased proliferation in cells lacking expression of Was compared to cells expressing Was in the follicular and germinal center B cell populations

Genotype
MGI:5319485

cn48

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Was^tm1.1Ldn/Y
• Genetic Background: involves: BALB/c * C57BL/6

immune system

increased germinal center B cell number ( J:182528 )

♂ • in the spleen and lymph nodes

increased plasma cell number ( J:182528 )

♂ • increase in the proportion of CD19+ CD138^hi plasma cells

decreased B cell number ( J:182528 )

♂ • B cell lymphopenia

decreased mature B cell number ( J:182528 )

♂ • decrease in the percentage and absolute number of bone marrow B220 hi mature recirculating B cells

♂ • decrease in the proportion and number of CD19+ B cells in the spleen

decreased follicular B cell number ( J:182528 )

♂ • decrease in absolute number but not the proportion of follicular B cells

decreased marginal zone B cell number ( J:182528 )

♂ • decrease in the percentage and absolute number of marginal zone B cells

♂ • the ring of B220+ CD1d+ MZ B cells that normally surrounds MOMA-expressing metallophilic macrophages is almost absent

abnormal B cell physiology ( J:182528 )

♂ • virtual abrogation of IgM and IgG pneumococcus polysaccharide specific Ab responses

♂ • abrogation of the early response to immunization with UV inactivated vesicular stomatitis virus

increased IgM level ( J:182528 )

♂ • elevated total serum levels and spontaneous production of IgM Abs specific for trinitrophenyl and phosphocholine

increased autoantibody level ( J:182528 )

♂

increased anti-chromatin antibody level ( J:182528 )

♂

increased anti-double stranded DNA antibody level ( J:182528 )

♂

increased anti-single stranded DNA antibody level ( J:182528 )

♂

renal/urinary system

abnormal renal corpuscle morphology ( J:182528 )

♂ • modest degree of glomerular damage

hematopoietic system

increased germinal center B cell number ( J:182528 )

♂ • in the spleen and lymph nodes

increased plasma cell number ( J:182528 )

♂ • increase in the proportion of CD19+ CD138^hi plasma cells

decreased B cell number ( J:182528 )

♂ • B cell lymphopenia

decreased mature B cell number ( J:182528 )

♂ • decrease in the percentage and absolute number of bone marrow B220 hi mature recirculating B cells

♂ • decrease in the proportion and number of CD19+ B cells in the spleen

decreased follicular B cell number ( J:182528 )

♂ • decrease in absolute number but not the proportion of follicular B cells

decreased marginal zone B cell number ( J:182528 )

♂ • decrease in the percentage and absolute number of marginal zone B cells

♂ • the ring of B220+ CD1d+ MZ B cells that normally surrounds MOMA-expressing metallophilic macrophages is almost absent

abnormal B cell physiology ( J:182528 )

♂ • virtual abrogation of IgM and IgG pneumococcus polysaccharide specific Ab responses

♂ • abrogation of the early response to immunization with UV inactivated vesicular stomatitis virus

increased IgM level ( J:182528 )

♂ • elevated total serum levels and spontaneous production of IgM Abs specific for trinitrophenyl and phosphocholine

Genotype
MGI:5008568

cn49

• Allelic Composition: Stim2^tm1.1Kuro/Stim2^tm1.1Kuro; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6

immune system

immune system phenotype ( J:172608 )

N • B cell proliferation in response to anti-IgM, anti-CD40, and LPS is normal

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit a mild decrease in calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

homeostasis/metabolism

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit a mild decrease in calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

hematopoietic system

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit a mild decrease in calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

Genotype
MGI:5008567

cn50

• Allelic Composition: Stim1^tm1Kuro/Stim1^tm1Kuro; Stim2^tm1.1Kuro/Stim2^tm1.1Kuro; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6

homeostasis/metabolism

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit little calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

immune system

immune system phenotype ( J:172608 )

N • mice exhibit normal B cell development

increased CD4-positive, alpha-beta T cell number ( J:172608 )

• following immunization with MOG35-55

increased CD8-positive, alpha-beta T cell number ( J:172608 )

• following immunization with MOG35-55

increased regulatory T cell number ( J:172608 )

• following immunization with MOG35-55

abnormal B cell physiology ( J:172608 )

• B cells treated with anti-IgM, anti-IgM and IL4, or anti-IgM and anti-CD40 exhibit reduced survival compared with control cells

• however, B cell treated with anti-CD40 or LPS exhibit normal survival and B cell antibody response is normal

decreased B cell proliferation ( J:172608 )

• B cells treated anti-IgM fail to exhibit proliferation unlike control cells

• B cells treated anti-IgM and IL4 exhibit reduced proliferation compared with control cells

• however, B cell proliferation stimulated by anti-CD40 or LPS is normal

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit little calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

increased interferon-gamma secretion ( J:172608 )

• in splenocytes following immunization with MOG35-55

decreased interleukin-10 secretion ( J:172608 )

• following stimulation with PMA and ionomycin, LPS, anti-IgM and anti-CD40, or anti-IgM and LPS

increased interleukin-10 secretion ( J:172608 )

• in splenocytes following immunization with MOG35-55

increased interleukin-17 secretion ( J:172608 )

• in splenocytes following immunization with MOG35-55

increased susceptibility to experimental autoimmune encephalomyelitis ( J:172608 )

• following immunization with MOG35-55, mice exhibit increased inflammatory cells infiltration (CD8+ and CD4+ T cells, T regulatory cells), demyelination, and cytokine production (IFN-gamma, IL17, and IL10) compared with control mice

nervous system

demyelination ( J:172608 )

• following immunization with MOG35-55

hematopoietic system

increased CD4-positive, alpha-beta T cell number ( J:172608 )

• following immunization with MOG35-55

increased CD8-positive, alpha-beta T cell number ( J:172608 )

• following immunization with MOG35-55

increased regulatory T cell number ( J:172608 )

• following immunization with MOG35-55

abnormal B cell physiology ( J:172608 )

• B cells treated with anti-IgM, anti-IgM and IL4, or anti-IgM and anti-CD40 exhibit reduced survival compared with control cells

• however, B cell treated with anti-CD40 or LPS exhibit normal survival and B cell antibody response is normal

decreased B cell proliferation ( J:172608 )

• B cells treated anti-IgM fail to exhibit proliferation unlike control cells

• B cells treated anti-IgM and IL4 exhibit reduced proliferation compared with control cells

• however, B cell proliferation stimulated by anti-CD40 or LPS is normal

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit little calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

cellular

decreased B cell proliferation ( J:172608 )

• B cells treated anti-IgM fail to exhibit proliferation unlike control cells

• B cells treated anti-IgM and IL4 exhibit reduced proliferation compared with control cells

• however, B cell proliferation stimulated by anti-CD40 or LPS is normal

Genotype
MGI:5008566

cn51

• Allelic Composition: Stim1^tm1Kuro/Stim1^tm1Kuro; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6

homeostasis/metabolism

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit less calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

immune system

decreased B cell proliferation ( J:172608 )

• anti-IgM-treated B cells exhibit decreased proliferation unlike control cells

• however, B cell proliferation stimulated by anti-CD40 or LPS is normal

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit less calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

decreased interleukin-10 secretion ( J:172608 )

• following PMA and ionomycin stimulation

hematopoietic system

decreased B cell proliferation ( J:172608 )

• anti-IgM-treated B cells exhibit decreased proliferation unlike control cells

• however, B cell proliferation stimulated by anti-CD40 or LPS is normal

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit less calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

cellular

decreased B cell proliferation ( J:172608 )

• anti-IgM-treated B cells exhibit decreased proliferation unlike control cells

• however, B cell proliferation stimulated by anti-CD40 or LPS is normal

Genotype
MGI:3687508

cn52

• Allelic Composition: Ikbkg^tm1.1Mpa/Ikbkg^tm1.1Mpa; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6

immune system

abnormal B cell differentiation ( J:113365 )

♀ • there is a pronounced block in B cell development at transition stage 1 in the spleen

decreased B cell number ( J:113365 )

♀ • mice show dramatic reduction in peripheral B cell numbers

decreased mature B cell number ( J:113365 )

♀ • numbers of mature B cells are reduced to 10% of levels in controls

hematopoietic system

abnormal B cell differentiation ( J:113365 )

♀ • there is a pronounced block in B cell development at transition stage 1 in the spleen

decreased B cell number ( J:113365 )

♀ • mice show dramatic reduction in peripheral B cell numbers

decreased mature B cell number ( J:113365 )

♀ • numbers of mature B cells are reduced to 10% of levels in controls

Genotype
MGI:7611733

cn53

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Phf5a^tm1.1Oux/Phf5a^tm1.1Oux; Tg(IghelMD4)4Ccg/0
• Genetic Background: involves: BALB/c * C57BL/6 * C57BL/6J

hematopoietic system

abnormal B cell number ( J:345807 )

• addition of a pre-rearranged IgH transgene partially but significantly increases the number of CD19+ B cells

immune system

abnormal B cell number ( J:345807 )

• addition of a pre-rearranged IgH transgene partially but significantly increases the number of CD19+ B cells

Genotype
MGI:5461328

cn54

• Allelic Composition: Bcl6^tm1.1Mtto/Bcl6^tm1.1Mtto; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6 * C57BL/6JJcl

immune system

abnormal somatic hypermutation frequency ( J:190943 )

• memory B cells from mice immunized with NP-CG fail to undergo somatic hypermutation compared with wild-type mice

decreased germinal center B cell number ( J:190943 )

• in mice immunized with NP-CG at day 5 and 7 (200-fold)

abnormal memory B cell morphology ( J:190943 )

• early germinal center memory B cells from mice immunized with NP-CG exhibit a resting state compared with wild-type mice

• however, the number of memory B cells is normal

abnormal memory B cell physiology ( J:190943 )

• 40 days after immunization with NP-CG, GC-independent memory B cells arise from dividing precursors, fail to exhibit a decrease in proliferation unlike wild-type cells and enter the memory compartment before germinal B cell progeny

abnormal humoral immune response ( J:190943 )

• memory B cells from mice treated with NP-CG produce low affinity antibodies in an IgG1 secondary response unlike wild-type cells

hematopoietic system

abnormal somatic hypermutation frequency ( J:190943 )

• memory B cells from mice immunized with NP-CG fail to undergo somatic hypermutation compared with wild-type mice

decreased germinal center B cell number ( J:190943 )

• in mice immunized with NP-CG at day 5 and 7 (200-fold)

abnormal memory B cell morphology ( J:190943 )

• early germinal center memory B cells from mice immunized with NP-CG exhibit a resting state compared with wild-type mice

• however, the number of memory B cells is normal

abnormal memory B cell physiology ( J:190943 )

• 40 days after immunization with NP-CG, GC-independent memory B cells arise from dividing precursors, fail to exhibit a decrease in proliferation unlike wild-type cells and enter the memory compartment before germinal B cell progeny

Genotype
MGI:5461331

cn55

• Allelic Composition: Bcl6^tm1.1Mtto/Bcl6^tm1.1Mtto; Cd79a^tm1(cre)Reth/Cd79a⁺; Tg(Cd4-cre)1Cwi/0
• Genetic Background: involves: BALB/c * C57BL/6 * C57BL/6JJcl * DBA/2

immune system

immune system phenotype ( J:190943 )

N • mice immunized with NP-CG exhibit normal development of memory B cells

decreased germinal center B cell number ( J:190943 )

• in mice immunized with NP-CG

hematopoietic system

decreased germinal center B cell number ( J:190943 )

• in mice immunized with NP-CG

Genotype
MGI:7646989

cn56

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Eif4b^tm1.1Tnr/Eif4b^tm1.1Tnr; Eif4h^{tm1c(EUCOMM)Wtsi}/Eif4h^{tm1c(EUCOMM)Wtsi}
• Genetic Background: involves: BALB/c * C57BL/6 * C57BL/6N

hematopoietic system

hematopoietic system phenotype ( J:344730 )

N • 7 days after immunization with 4-hydroxy-3-nitrophenyl-acetyl conjugated to keyhole limpet hemocyanin B cell numbers are similar to immunized controls

decreased mature B cell number ( J:344730 )

• small reduction (25%) in mature/recirculating B cells

• normal numbers of splenic B cells and fractions of B-E B cells in the bone marrow

decreased IgG1 level ( J:344730 )

• small reduction in high-affinity IgG1 antibodies at 14 days after immunization with 4-hydroxy-3-nitrophenyl-acetyl conjugated to keyhole limpet hemocyanin

immune system

decreased mature B cell number ( J:344730 )

• small reduction (25%) in mature/recirculating B cells

• normal numbers of splenic B cells and fractions of B-E B cells in the bone marrow

decreased IgG1 level ( J:344730 )

• small reduction in high-affinity IgG1 antibodies at 14 days after immunization with 4-hydroxy-3-nitrophenyl-acetyl conjugated to keyhole limpet hemocyanin

Genotype
MGI:7625698

cn57

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Orai1^tm1Smua/Orai1^tm1Smua
• Genetic Background: involves: BALB/c * C57BL/6J

immune system

immune system phenotype ( J:345485 )

N • no defects in B cell development in the bone marrow or spleen

abnormal B cell physiology ( J:345485 )

• store-operated Ca2+ entry (SOCE) in B cells is reduced by~69%

• however, agonist induced Ca2+ oscillations are similar to controls

• residual SOCE activity is not inhibited by 2-aminoethyl diphenyl borate (2-APB)

• anti-IgM mediated NFAT1 translocation is significantly reduced

abnormal B cell activation ( J:345485 )

• following anti-IgM stimulation proliferation is similar to controls but cell viability is moderately reduced

• increase in oxygen consumption rate and extracellular acidification rates following B cell receptor activation is significantly blunted

homeostasis/metabolism

abnormal calcium ion homeostasis ( J:345485 )

• store-operated Ca2+ entry (SOCE) in B cells is reduced by~69%

• residual SOCE activity in B cells is not inhibited by 2-aminoethyl diphenyl borate (2-APB)

• however, agonist induced Ca2+ oscillations in B cells are similar to controls

hematopoietic system

abnormal B cell physiology ( J:345485 )

• store-operated Ca2+ entry (SOCE) in B cells is reduced by~69%

• however, agonist induced Ca2+ oscillations are similar to controls

• residual SOCE activity is not inhibited by 2-aminoethyl diphenyl borate (2-APB)

• anti-IgM mediated NFAT1 translocation is significantly reduced

abnormal B cell activation ( J:345485 )

• following anti-IgM stimulation proliferation is similar to controls but cell viability is moderately reduced

• increase in oxygen consumption rate and extracellular acidification rates following B cell receptor activation is significantly blunted

Genotype
MGI:7611716

cn58

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Phf5a^tm1.1Oux/Phf5a^tm1.1Oux
• Genetic Background: involves: BALB/c * C57BL/6J

hematopoietic system

abnormal B cell receptor editing ( J:345807 )

• defect in RAG-mediated recombination

abnormal immunoglobulin heavy chain V(D)J recombination ( J:345807 )

• significant reduction in the diversity of IgH chain repetoires

decreased early pro-B cell number ( J:345807 )

• decreased absolute numbers of BP1- CD24+ early pro-B cells

decreased late pro-B cell number ( J:345807 )

• decreased absolute numbers of BP1+ CD24^high late pro-B cells

increased pre-pro B cell number ( J:345807 )

• increase in frequency and absolute number of BP1- CD24- pre-pro-B cells

• no increase in proliferation of pre-pro-B cells

decreased B cell number ( J:345807 )

• approximately sixfold decrease in both percentage and total number of B220+ B cells in the bone marrow

• percentages and absolute numbers of B220+ CD43- late-stage B cells and B220^high CD43- recirculating B cells are decreased

• severe B lymphopenia in the periphery

decreased immature B cell number ( J:345807 )

• drastically reduced B220+ CD43+ IgM+ IgD- immature B cell numbers

decreased mature B cell number ( J:345807 )

• dramatic reduction in the number of B220+ splenic B cells

• IgD+ mature B cells are virtually absent in the spleen

decreased pre-B cell number ( J:345807 )

• drastically reduced B220+ CD43- IgM- IgD- small pre-B cell numbers

small spleen ( J:345807 )

abnormal B cell physiology ( J:345807 )

• defect in IgH chain gene expression in pre-pro-B cells

immune system

abnormal B cell receptor editing ( J:345807 )

• defect in RAG-mediated recombination

abnormal immunoglobulin heavy chain V(D)J recombination ( J:345807 )

• significant reduction in the diversity of IgH chain repetoires

decreased early pro-B cell number ( J:345807 )

• decreased absolute numbers of BP1- CD24+ early pro-B cells

decreased late pro-B cell number ( J:345807 )

• decreased absolute numbers of BP1+ CD24^high late pro-B cells

increased pre-pro B cell number ( J:345807 )

• increase in frequency and absolute number of BP1- CD24- pre-pro-B cells

• no increase in proliferation of pre-pro-B cells

decreased B cell number ( J:345807 )

• approximately sixfold decrease in both percentage and total number of B220+ B cells in the bone marrow

• percentages and absolute numbers of B220+ CD43- late-stage B cells and B220^high CD43- recirculating B cells are decreased

• severe B lymphopenia in the periphery

decreased immature B cell number ( J:345807 )

• drastically reduced B220+ CD43+ IgM+ IgD- immature B cell numbers

decreased mature B cell number ( J:345807 )

• dramatic reduction in the number of B220+ splenic B cells

• IgD+ mature B cells are virtually absent in the spleen

decreased pre-B cell number ( J:345807 )

• drastically reduced B220+ CD43- IgM- IgD- small pre-B cell numbers

small spleen ( J:345807 )

abnormal B cell physiology ( J:345807 )

• defect in IgH chain gene expression in pre-pro-B cells

Genotype
MGI:7625702

cn59

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Orai1^tm1Smua/Orai1^tm1Smua; Orai3^em1.1Treb/Orai3^em1.1Treb
• Genetic Background: involves: BALB/c * C57BL/6J * C57BL/6N

immune system

immune system phenotype ( J:345485 )

N • immune responses to influenza A infection are similar to controls

abnormal B cell physiology ( J:345485 )

• store-operated Ca2+ entry in B cells is reduced by~83%

• anti-IgM mediated NFAT1 translocation is significantly reduced

abnormal B cell activation ( J:345485 )

• increase in oxygen consumption rate and extracellular acidification rates following B cell receptor activation is significantly blunted

decreased B cell proliferation ( J:345485 )

• decrease in both proliferation and viablity of cells following anti-IgM stimulation

hematopoietic system

abnormal B cell physiology ( J:345485 )

• store-operated Ca2+ entry in B cells is reduced by~83%

• anti-IgM mediated NFAT1 translocation is significantly reduced

abnormal B cell activation ( J:345485 )

• increase in oxygen consumption rate and extracellular acidification rates following B cell receptor activation is significantly blunted

decreased B cell proliferation ( J:345485 )

• decrease in both proliferation and viablity of cells following anti-IgM stimulation

homeostasis/metabolism

abnormal calcium ion homeostasis ( J:345485 )

• store-operated Ca2+ entry in B cells is reduced by~83%

cellular

decreased B cell proliferation ( J:345485 )

• decrease in both proliferation and viablity of cells following anti-IgM stimulation

Genotype
MGI:7625703

cn60

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Orai3^em1.1Treb/Orai3^em1.1Treb
• Genetic Background: involves: BALB/c * C57BL/6J * C57BL/6N

immune system

immune system phenotype ( J:345485 )

N • store-operated Ca2+ entry in B cells is not significantly different from controls

abnormal B cell activation ( J:345485 )

• anti-IgM stimulated proliferation is similar to control but viability is increased

hematopoietic system

abnormal B cell activation ( J:345485 )

• anti-IgM stimulated proliferation is similar to control but viability is increased

Genotype
MGI:3797395

cn61

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Dicer1^tm1Mmk/Dicer1^tm1Mmk; Tg(BCL2)22Wehi/0
• Genetic Background: involves: BALB/c * C57BL/6JWehi * SJL/JWehi

immune system

decreased B cell number ( J:135783 )

• while B cell numbers are increased relative to in Cd79a^tm1(cre)Reth/Cd79a⁺ Dicer1^tm1Mmk/Dicer1^tm1Mmk mice, numbers are still lower than in wild-type mice

decreased mature B cell number ( J:135783 )

hematopoietic system

decreased B cell number ( J:135783 )

• while B cell numbers are increased relative to in Cd79a^tm1(cre)Reth/Cd79a⁺ Dicer1^tm1Mmk/Dicer1^tm1Mmk mice, numbers are still lower than in wild-type mice

decreased mature B cell number ( J:135783 )

Genotype
MGI:5550380

cn62

• Allelic Composition: Rnf31^tm1.1Kiwa/Rnf31^tm1.1Kiwa; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6NCrlj * CBA/JNCrlj

immune system

immune system phenotype ( J:201885 )

N • mice exhibit normal conventional B cell development and I cell populations

abnormal B-1 B cell morphology ( J:201885 )

• severely impaired B1 B cell development in the peritoneal cavity

decreased B-1a cell number ( J:201885 )

• in the peritoneal cavity

decreased B-1b cell number ( J:201885 )

• in the peritoneal cavity

abnormal humoral immune response ( J:201885 )

• impaired antibody responses to both T cell-dependent and T cell-independent type 2 antigens

decreased IgA level ( J:201885 )

• in unimmunized mice

decreased IgG1 level ( J:201885 )

• in unimmunized mice

• in mice immunized with NP-CGG

decreased IgG2a level ( J:201885 )

• in unimmunized mice

decreased IgG2b level ( J:201885 )

• in unimmunized mice

decreased IgG3 level ( J:201885 )

• in unimmunized mice

• in mice immunized with NP-Ficoll

decreased IgM level ( J:201885 )

• in unimmunized mice

• in mice immunized with NP-CGG or NP-Ficoll

hematopoietic system

abnormal B-1 B cell morphology ( J:201885 )

• severely impaired B1 B cell development in the peritoneal cavity

decreased B-1a cell number ( J:201885 )

• in the peritoneal cavity

decreased B-1b cell number ( J:201885 )

• in the peritoneal cavity

decreased IgA level ( J:201885 )

• in unimmunized mice

decreased IgG1 level ( J:201885 )

• in unimmunized mice

• in mice immunized with NP-CGG

decreased IgG2a level ( J:201885 )

• in unimmunized mice

decreased IgG2b level ( J:201885 )

• in unimmunized mice

decreased IgG3 level ( J:201885 )

• in unimmunized mice

• in mice immunized with NP-Ficoll

decreased IgM level ( J:201885 )

• in unimmunized mice

• in mice immunized with NP-CGG or NP-Ficoll

Genotype
MGI:6358356

cn63

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Commd8^tm1.1Ksuz/Commd8^tm1.1Ksuz
• Genetic Background: involves: BALB/c * C57BL/6NSlc * SJL

immune system

immune system phenotype ( J:278399 )

N • mice exhibit normal size of developing B cell subsets and serum levels of IgA in unimmunized mice

decreased mature B cell number ( J:278399 )

• in the bone marrow, blood, and spleen

decreased follicular B cell number ( J:278399 )

• in the bone marrow, blood, and spleen

abnormal plasmablast number ( J:278399 )

• decreased after immunization with NP-CGG compared with controls

abnormal spleen B cell follicle morphology ( J:278399 )

• less defined boundaries

decreased spleen germinal center number ( J:278399 )

• after immunization with NP-CGG compared with controls

abnormal follicular B cell physiology ( J:278399 )

• impaired B cell migration in response to CXCL12, CXCL13, CCL19 and 7alpha,25-HC

• bone marrow chimeras exhibit increased migration of B cells from follicles compared with wild-derived cells

• however, response to S1P is normal as is lymph node egression

decreased IgG1 level ( J:278399 )

• in unimmunized mice and after immunization with NP-CGG compared with controls

decreased IgG2b level ( J:278399 )

• in unimmunized mice

decreased IgG2c level ( J:278399 )

• in unimmunized mice

decreased IgG3 level ( J:278399 )

• in unimmunized mice

decreased IgM level ( J:278399 )

• after immunization with NP-CGG compared with controls

• however, unimmunized mice exhibit normal levels of IgM

hematopoietic system

decreased mature B cell number ( J:278399 )

• in the bone marrow, blood, and spleen

decreased follicular B cell number ( J:278399 )

• in the bone marrow, blood, and spleen

abnormal plasmablast number ( J:278399 )

• decreased after immunization with NP-CGG compared with controls

abnormal spleen B cell follicle morphology ( J:278399 )

• less defined boundaries

decreased spleen germinal center number ( J:278399 )

• after immunization with NP-CGG compared with controls

abnormal follicular B cell physiology ( J:278399 )

• impaired B cell migration in response to CXCL12, CXCL13, CCL19 and 7alpha,25-HC

• bone marrow chimeras exhibit increased migration of B cells from follicles compared with wild-derived cells

• however, response to S1P is normal as is lymph node egression

decreased IgG1 level ( J:278399 )

• in unimmunized mice and after immunization with NP-CGG compared with controls

decreased IgG2b level ( J:278399 )

• in unimmunized mice

decreased IgG2c level ( J:278399 )

• in unimmunized mice

decreased IgG3 level ( J:278399 )

• in unimmunized mice

decreased IgM level ( J:278399 )

• however, unimmunized mice exhibit normal levels of IgM

• after immunization with NP-CGG compared with controls

Genotype
MGI:6358355

cn64

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Commd3^tm1.1Ksuz/Commd3^tm1.1Ksuz
• Genetic Background: involves: BALB/c * C57BL/6NSlc * SJL

immune system

immune system phenotype ( J:278399 )

N • mice exhibit normal size of developing B cell subsets and serum levels of IgG3 and IgA in unimmunized mice

decreased mature B cell number ( J:278399 )

• in the bone marrow, blood, and spleen

decreased follicular B cell number ( J:278399 )

• in the bone marrow, blood, and spleen

abnormal plasmablast number ( J:278399 )

• decreased after immunization with NP-CGG compared with controls

abnormal spleen B cell follicle morphology ( J:278399 )

• less defined boundaries

decreased spleen germinal center number ( J:278399 )

• after immunization with NP-CGG compared with controls

abnormal follicular B cell physiology ( J:278399 )

• impaired B cell migration in response to CXCL12, CXCL13, CCL19 and 7alpha,25-HC

• bone marrow chimeras exhibit increased migration of B cells from follicles compared with wild-derived cells

• however, response to S1P is normal as is lymph node egression

decreased IgG1 level ( J:278399 )

• in unimmunized mice and after immunization with NP-CGG compared with controls

decreased IgG2b level ( J:278399 )

• in unimmunized mice

decreased IgG2c level ( J:278399 )

• in unimmunized mice

decreased IgM level ( J:278399 )

• in unimmunized mice and after immunization with NP-CGG compared with controls

hematopoietic system

decreased mature B cell number ( J:278399 )

• in the bone marrow, blood, and spleen

decreased follicular B cell number ( J:278399 )

• in the bone marrow, blood, and spleen

abnormal plasmablast number ( J:278399 )

• decreased after immunization with NP-CGG compared with controls

abnormal spleen B cell follicle morphology ( J:278399 )

• less defined boundaries

decreased spleen germinal center number ( J:278399 )

• after immunization with NP-CGG compared with controls

abnormal follicular B cell physiology ( J:278399 )

• impaired B cell migration in response to CXCL12, CXCL13, CCL19 and 7alpha,25-HC

• bone marrow chimeras exhibit increased migration of B cells from follicles compared with wild-derived cells

• however, response to S1P is normal as is lymph node egression

decreased IgG1 level ( J:278399 )

• in unimmunized mice and after immunization with NP-CGG compared with controls

decreased IgG2b level ( J:278399 )

• in unimmunized mice

decreased IgG2c level ( J:278399 )

• in unimmunized mice

decreased IgM level ( J:278399 )

• in unimmunized mice and after immunization with NP-CGG compared with controls

Genotype
MGI:5296788

cn65

• Allelic Composition: Sh3kbp1^tm1Kuro/Sh3kbp1^tm1Kuro; Cd79a^tm1(cre)Reth/Cd79a⁺; Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky}/?
• Genetic Background: involves: BALB/c * C57BL/6 * NZB

immune system

immune system phenotype ( J:176805 )

♀N • T cell independent type II antibody responses are restored

decreased B-1a cell number ( J:176805 )

♀ • B-1a cell development continues to be defective

hematopoietic system

decreased B-1a cell number ( J:176805 )

♀ • B-1a cell development continues to be defective

Genotype
MGI:5296787

cn66

• Allelic Composition: Sh3kbp1^tm1Kuro/Sh3kbp1^tm1Kuro; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6 * NZB

immune system

immune system phenotype ( J:176805 )

♀N • no gross development arrest in bone marrow

abnormal lymphocyte cell number ( J:176805 )

♀

decreased B cell number ( J:176805 )

♀ • recirculating B cells reduced about 20%

decreased immature B cell number ( J:176805 )

♀ • reduced about 20%

decreased transitional stage T2 B cell number ( J:176805 )

♀ • reduced about 20% in the spleen

decreased transitional stage T3 B cell number ( J:176805 )

♀ • reduced about 20% in the spleen

decreased B-1a cell number ( J:176805 )

♀ • peritoneal B-1a B cells are reduced about 8 fold

decreased follicular B cell number ( J:176805 )

♀ • reduced about 20% in the spleen

abnormal B cell physiology ( J:176805 )

♀ • antigen specific B cells fail to increase due to T cell independent type II antibody response

♀ • B cell proliferation after anti-IgM stimulation is severely reduced

abnormal humoral immune response ( J:176805 )

♀ • T cell independent type II antibody responses are considerably reduced

hematopoietic system

abnormal lymphocyte cell number ( J:176805 )

♀

decreased B cell number ( J:176805 )

♀ • recirculating B cells reduced about 20%

decreased immature B cell number ( J:176805 )

♀ • reduced about 20%

decreased transitional stage T2 B cell number ( J:176805 )

♀ • reduced about 20% in the spleen

decreased transitional stage T3 B cell number ( J:176805 )

♀ • reduced about 20% in the spleen

decreased B-1a cell number ( J:176805 )

♀ • peritoneal B-1a B cells are reduced about 8 fold

decreased follicular B cell number ( J:176805 )

♀ • reduced about 20% in the spleen

abnormal B cell physiology ( J:176805 )

♀ • antigen specific B cells fail to increase due to T cell independent type II antibody response

♀ • B cell proliferation after anti-IgM stimulation is severely reduced

Genotype
MGI:5316371

cn67

• Allelic Composition: Ebf1^tm1.1Rug/Ebf1^tm1.1Rug; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6 * SJL

immune system

arrested B cell differentiation ( J:182210 )

• at the pre-pro-B cell stage, not rescued by over-expression of Bcl2

hematopoietic system

arrested B cell differentiation ( J:182210 )

• at the pre-pro-B cell stage, not rescued by over-expression of Bcl2